EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy

Janelle M Montagne iD, Elizabeth M Jaffee iD, Elana J Fertig

The Journal of Immunology · 2023

DOI: 10.4049/jimmunol.2200660 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Janelle M Montagne und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute, Johns Hopkins University Discovery Awards.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in cancer immunotherapy, particularly immune checkpoint inhibitors, have dramatically improved the prognosis for patients with metastatic melanoma and other previously incurable cancers. However, patients with pancreatic ductal adenocarcinoma (PDAC) generally do not respond to these therapies. PDAC is exceptionally difficult to treat because of its often late stage at diagnosis, modest mutation burden, and notoriously complex and immunosuppressive tumor microenvironment. Simultaneously interrogating features of cancer, immune, and other cellular components of the PDAC tumor microenvironment is therefore crucial for identifying biomarkers of immunotherapeutic resistance and response. Notably, single-cell and multiomics technologies, along with the analytical tools for interpreting corresponding data, are facilitating discoveries of the systems-level cellular and molecular interactions contributing to the overall resistance of PDAC to immunotherapy. Thus, in this review, we will explore how multiomics and single-cell analyses provide the unprecedented opportunity to identify biomarkers of resistance and response to successfully sensitize PDAC to immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansMultiomicsImmunotherapyBiomarkersTumor Microenvironment

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Bloomberg Kimmel Immunology Institute, Johns Hopkins University School of Medicine, Baltimore, MD.

ORCID-Profile: Janelle M Montagne, Elizabeth M Jaffee

Förderung

  • NCI NIH HHS
  • HHS | NIH | National Cancer Institute
  • Johns Hopkins University Discovery Awards
  • Lustgarten Foundation

Zitieren

APA

Montagne, J. M., Jaffee, E. M., & Fertig, E. J. (2023). Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200660

Vancouver

Montagne JM, Jaffee EM, Fertig EJ. Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2200660

BibTeX
@article{Montagne2023,
  author = {Montagne, Janelle M and Jaffee, Elizabeth M and Fertig, Elana J},
  title = {Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy},
  journal = {The Journal of Immunology},
  year = {2023},
  doi = {10.4049/jimmunol.2200660}
}
Kostenlos starten →